Fig. 3

IRF1 targets miR-16-5p and increases its expression in fibroblasts. A The motif and binding site of the upstream transcription factor IRF1 of miR-16-5p predicted by miRGen database. B IRF1 expression in normal foot tissues of normal rats and foot wound tissues of non-DM and DM rats detected by RT-qPCR. *p < 0.05 vs. normal rats; # p < 0.05 vs. non-DM rats. C Binding of IRF1 to the miR-16-5p promoter identified by dual-luciferase reporter assay. * p < 0.05 vs. the pMIR group. D Direct binding of IRF1 to miR-16-5p detected by RNA pull-down assay. E Binding of IRF1 to miR-16-5p validated by ChIP assay. *p < 0.05 vs. IgG group. F The expression of IRF1 and miR-16-5p in fibroblasts treated with oe-IRF1 or sh-IRF1 determined by RT-qPCR. *p < 0.05 vs. the fibroblasts treated with oe-NC. #p < 0.05 vs. the fibroblasts treated with sh-NC. Cell experiments were repeated three times. n = 8. Measurement data were presented as mean ± standard deviation. Data among multiple groups were compared by one-way ANOVA, followed by Tukey’s post hoc test for multiple comparisons